Skip to main content
Caplight Logo









Breakpoint Therapeutics

Breakpoint Therapeutics

Private
HamburgHealthcare & Life Scienceshttps://breakpointtx.com/

Last Round

Series A

Extension

Oct 18, 2021

Total Funding Raised

$33.6M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Breakpoint Therapeutics is a biotechnology company that discovers and develops anti-cancer drugs targeting DNA damage response mechanisms in cancer cells.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

DNA repair inhibitorssynthetic lethalityoncology drug discoverysmall-molecule therapeuticsDDR inhibitorsDNA damage responsecancer drug developmentpreclinical biotechtargeted cancer therapydrug out-licensingprecision oncologybiotech spin-off

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Breakpoint Therapeutics Comparables

Compare Breakpoint Therapeutics with similar companies based on industry and business-model similarity.

Breakpoint Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
FoRx Therapeutics
86%
CV6 Therapeutics
84%
SynRx Therapeutics
84%

Breakpoint Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series A ExtensionOct 18, 2021
Series AJul 8, 2019

Breakpoint Therapeutics Investors

Notable investors and investment history

Breakpoint Therapeutics investors
InvestorRounds
Taiho VenturesSeries A
BVF Partners L.P.Series A Extension
MedicxiSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 21, 2026

    Monthly visitors grew 732% MoM, from 99 to 824.

  • May 15, 2026

    Monthly visitors grew 315% MoM, from 445 to 1.8K.

Breakpoint Therapeutics Filings

Explore SEC and related filing metadata, where available.

Breakpoint Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Breakpoint Therapeutics's valuation, stock price, and market status.

Is Breakpoint Therapeutics a public or private company?

Breakpoint Therapeutics is a private company.

What is the current stock price of Breakpoint Therapeutics?

Breakpoint Therapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is Breakpoint Therapeutics worth (valuation)?

Valuation information for Breakpoint Therapeutics is not publicly available.

Can I buy Breakpoint Therapeutics stock?

Breakpoint Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Breakpoint Therapeutics's last funding round?

Breakpoint Therapeutics's most recent funding round was Series A Extension on October 18, 2021.

Who are the main investors in Breakpoint Therapeutics?

Key investors in Breakpoint Therapeutics include Medicxi.

Will Breakpoint Therapeutics IPO soon?

No public IPO plans have been announced for Breakpoint Therapeutics.

How can I track Breakpoint Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Breakpoint Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersHamburg
Employee Range3
Year Founded2019
Last FundingOct 18, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?